Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia
oleh: A. Kalff, J. Shortt, J. Farr, R. McLennan, A. Lui, J. Scott, A. Spencer
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2008-01-01 |
Deskripsi
LBH589 is a novel cinnamic hydroxamic acid analog (HAA) pan-histone deacetylase inhibitor (HDACi) currently in early phase clinical development.